The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation

References

• Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tiss Kin. 1970;3:393–403.
   PubMedGoogle Scholar
• Can A, Karahuseyinoglu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells. 2007;25:2886–95.
   PubMed Web of Science ®Google Scholar
• Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, . Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells. 2004;22:1330–7.
   PubMed Web of Science ®Google Scholar
• Troyer DL, Weiss ML. Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells. 2008; 26: 591–9.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, . Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005; 7:393–5.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
   PubMed Web of Science ®Google Scholar
• Sensebe L, Bourin P. Mesenchymal stem cells for therapeutic purposes. Transplantation. 2009;87:S49–53.
   PubMedGoogle Scholar
• Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.
   PubMed Web of Science ®Google Scholar
• Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, . Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation. 2007;84:231–7.
   PubMed Web of Science ®Google Scholar
• Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, . Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3 + regulatory T cells. Stem Cells. 2008;26:212–22.
   PubMed Web of Science ®Google Scholar
• Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, . Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells. 2008;26:1275–87.
   PubMed Web of Science ®Google Scholar
• Renner P, Eggenhofer E, Rosenauer A, Popp FC, Steinmann JF, Slowik P, . Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc. 2009;41:2607–11.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Yen ML, Chen YC, Chien CC, Huang HI, Bai CH, . Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells. 2006;24:2466–77.
   PubMed Web of Science ®Google Scholar
• Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353–63.
   PubMed Web of Science ®Google Scholar
• Muller I, Lymperi S, Dazzi F. Mesenchymal stem cell therapy for degenerative inflammatory disorders. Curr Opin Organ Transplant. 2008;13:639–44.
   PubMed Web of Science ®Google Scholar
• Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, . Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol. 2009;259:150–6.
   PubMed Web of Science ®Google Scholar
• Delarosa O, Lombardo E, Beraza A, Mancheno P, Ramirez C, Menta R, . Requirement of IFN-gamma-mediated indoleamine 2,3 dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A. 2009;15:2795–806.
   PubMed Web of Science ®Google Scholar
• Cohen JL, Sudres M. A role for mesenchymal stem cells in the control of graft-versus-host disease. Transplantation. 2009;87:S53–4.
   Google Scholar
• Sessarego N, Parodi A, Podesta M, Benvenuto F, Mogni M, Raviolo V, . Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica. 2008;93:339–46.
   PubMed Web of Science ®Google Scholar
• Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, VanderWerff I, . Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells. 2008;26:2865–74.
   PubMed Web of Science ®Google Scholar
• Girdlestone J, Limbani VA, Cutler AJ, Navarrete CV. Efficient expansion of mesenchymal stromal cells from umbilical cord under low serum conditions. Cytotherapy. 2009;11:738–48.
   PubMed Web of Science ®Google Scholar
• Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, . Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and autoimmune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology. 2007;46:403–8.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 2008;251:131–6.
   PubMed Web of Science ®Google Scholar
• Siegel G, Schafer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation. 2009;87:S45–9.
   PubMed Web of Science ®Google Scholar
• Belladonna ML, Puccetti P, Orabona C, Fallarino F, Vacca C, Volpi C, . Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation. 2007;84:S17–20.
   PubMedGoogle Scholar
• Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, . Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386–98.
   PubMed Web of Science ®Google Scholar
• Yang SH, Park MJ, Yoon IH, Kim SY, Hong SH, Shin JY, . Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med. 2009;41:315–24.
   PubMed Web of Science ®Google Scholar
• Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, . IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745–55.
   PubMed Web of Science ®Google Scholar